Tonix Pharmaceuticals Holding short interest in 2022
In 2022, Tonix Pharmaceuticals Holding's disclosed short interest ran from 1.95% of shares outstanding on 14 Jan 2022 to 5.84% on 30 Dec 2022, a change of +3.89 percentage points. The year's high was 8.44% on 29 Apr 2022 and its low 1.07% on 15 Nov 2022, averaging 4.61% across 15 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 2.58 days on 29 Apr 2022. Full history: Tonix Pharmaceuticals Holding.
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2025 · 2026
2022 in figures
- Start of year
- 1.95% (14 Jan 2022)
- End of year
- 5.84% (30 Dec 2022)
- Change
- +3.89 pp
- High
- 8.44% (29 Apr 2022)
- Low
- 1.07% (15 Nov 2022)
- Average
- 4.61%
- Highest days to cover
- 2.58 (29 Apr 2022)
- SEC filings marked
- 10
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 1.95% | 1.00 | |
| 15 Mar 2022 | 5.40% | 1.00 | 10-K filed, results (8-K) |
| 31 Mar 2022 | 6.00% | 1.23 | |
| 14 Apr 2022 | 6.93% | 1.43 | |
| 29 Apr 2022 | 8.44% | 2.58 | |
| 13 May 2022 | 7.87% | 2.36 | 10-Q filed, results (8-K) |
| 15 Aug 2022 | 5.81% | 1.00 | results (8-K), 10-Q filed, results (8-K) |
| 31 Aug 2022 | 5.57% | 1.00 | |
| 15 Sep 2022 | 4.42% | 1.00 | |
| 30 Sep 2022 | 2.58% | 1.00 | |
| 14 Oct 2022 | 2.63% | 1.00 | |
| 31 Oct 2022 | 2.20% | 1.00 | results (8-K) |
| 15 Nov 2022 | 1.07% | 1.00 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 2.39% | 1.00 | |
| 30 Dec 2022 | 5.84% | 1.17 |
See also: Tonix Pharmaceuticals Holding's full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.